藥明生(sheng)物2024年上半(ban)年收(shou)(shou)(shou)益達人(ren)民幣85.7億(yi)元，同(tong)比增長1.0%。非(fei)新冠項(xiang)目(mu)(mu)收(shou)(shou)(shou)益增長7.7%，臨(lin)(lin)床后期(qi)及商(shang)業化(hua)生(sheng)產項(xiang)目(mu)(mu)收(shou)(shou)(shou)益增長11.7%。新增61個(ge)綜(zong)合項(xiang)目(mu)(mu)，總數達742個(ge)。集團臨(lin)(lin)床后期(qi)項(xiang)目(mu)(mu)增加至56個(ge)，為未來(lai)商(shang)業化(hua)生(sheng)產奠定(ding)堅實基礎。純(chun)利17.8億(yi)元，同(tong)比下降23.9%；經調整(zheng)純(chun)利25.4億(yi)元，同(tong)比下降13%。(美通社(she))